Know Cancer

or
forgot password

A Prospective Cohort Study Assessing the Efficacy and Safety of Tarceva in 2nd Line in Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)


N/A
18 Years
N/A
Open (Enrolling)
Both
Non-Small Cell Lung Cancer

Thank you

Trial Information

A Prospective Cohort Study Assessing the Efficacy and Safety of Tarceva in 2nd Line in Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)


Inclusion Criteria:



- Adult patients, >/= 18 years of age

- Histologically or cytologically confirmed advanced (Stage IIIB) or metastatic (Stage
IV) squamous non-small cell lung cancer after failure of first-line platinum-based
chemotherapy

- Patients for whom the treating physician has decided to initiate treatment with
Tarceva

Exclusion Criteria:

- Mixed non-small cell and small-cell lung carcinoma or mixed squamous cell carcinoma
with predominant adenocarcinoma component

- Current participation in a clinical trial evaluating an anticancer treatment

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Progression-free survival

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

Hoffmann-La Roche

Authority:

France: Commission Nationale de l'Informatique et des Libert├ęs (CNIL)

Study ID:

ML28195

NCT ID:

NCT01659970

Start Date:

June 2012

Completion Date:

May 2014

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location